Navigation Links
Eurand Added to NASDAQ Biotechnology Index
Date:11/12/2007

AMSTERDAM, Netherlands, Nov. 12 /PRNewswire-FirstCall/ -- Eurand N.V. (Nasdaq: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, announced today that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), effective November 19, 2007.

Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We are delighted to be included in this important NASDAQ index and believe it is further validation of our position in the life sciences industry."

The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies that meet eligibility criteria including market capitalization minimums, trading volume minimums, and ICB classification. The index is ranked on a semi-annual basis in May and November. More information about the NBI is available at http://www.nasdaq.com

About Eurand

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and filed a rolling NDA for this product which the company anticipates to complete by the end of 2007. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-making/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at http://www.eurand.com.

This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward- looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward- looking statements.

Contacts:

Mario Crovetto Nick Laudico/Elizabeth Scott

Chief Financial Officer The Ruth Group

Eurand N.V. 646-536-7030/7014

+39 02 95428 521 nlaudico@theruthgroup.com

mario.crovetto@eurand.com escott@theruthgroup.com


'/>"/>
SOURCE Eurand N.V.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
6. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
7. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
8. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee is pleased to announce ... a volunteer member of Committee since 1987. Since then, he has served in a ... and was chairman for both the program and exposition committees. In his professional career, ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, 2016 ... announced today that Martine Rothblatt , Ph.D., Chairman ... an overview and update on the company,s business at ... Conference. The presentation will take place on ... and can be accessed via a live webcast on ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a ... Board. Dr. Lamka will assist PathSensors in expanding the use of the company’s ... the CANARY® test platform for the detection of harmful pathogens, including a number ...
(Date:4/27/2016)... ... 2016 , ... Global Stem Cells Group and the University of ... research and development initiatives for potential stem cell protocol management for 2016 – 2020. ... executives began meeting to establish a working agenda and foster initiatives to promote stem ...
Breaking Biology Technology:
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
Breaking Biology News(10 mins):